Rilzabrutinib Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Rilzabrutinib Growth

1. First-in-class approval in immune thrombocytopenia (ITP)

• Rilzabrutinib became the first Bruton’s tyrosine kinase (BTK) inhibitor approved for ITP in the US and EU.
• Targets root disease biology via multi-immune modulation (B cells + innate immunity).
• First-in-class positioning → strong differentiation and rapid uptake potential
• Enables premium pricing and guideline inclusion

2. Robust Phase III efficacy (LUNA 3 trial)

• Phase III results showed:
• 65% platelet response vs 33% placebo
• Durable platelet response and reduced bleeding events
• Demonstrated improvements in quality of life and fatigue
• Strong efficacy vs placebo → high physician confidence and adoption
• Supports positioning in refractory patient populations

3. Large unmet need in ITP and rare hematology

• ~25,000+ adults in the US could benefit from advanced ITP treatments
• Patients often fail multiple prior therapies (median ~4 prior treatments in trials)

4. Broad pipeline expansion across immune-mediated diseases

• Rilzabrutinib is being studied in:
• IgG4-related disease (orphan designation in Japan)
• Warm autoimmune hemolytic anemia, asthma, chronic urticaria, SCD
• Multi-indication expansion → significant label expansion potential
• Increases long-term peak sales ceiling beyond ITP

5. Favorable mechanism and oral administration advantage

• Oral, reversible BTK inhibitor with selective target binding (TAILORED COVALENCY® technology)
• Targets both adaptive and innate immune pathways

Rilzabrutinib Recent Developments

• In February 2026, The US Food and Drug Administration (FDA) granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune disorder marked by the destruction of red blood cells. The Japanese Ministry of Health, Labour and Welfare has also provided rilzabrutinib an orphan designation for the same condition.

“Rilzabrutinib Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Rilzabrutinib for approved indication like Idiopathic thrombocytopenic purpura; as well as potential indication like Autoimmune haemolytic anaemia, Immunoglobulin G4-related disease, Asthma, Chronic urticaria, and Sickle cell anaemia in the 7MM. A detailed picture of Rilzabrutinib’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Rilzabrutinib for approved and potential indications. The Rilzabrutinib market report provides insights about Rilzabrutinib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Rilzabrutinib performance, future market assessments inclusive of the Rilzabrutinib market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Rilzabrutinib sales forecasts, along with factors driving its market.

Rilzabrutinib Drug Summary

Rilzabrutinib is an investigational, orally administered reversible Bruton’s tyrosine kinase (BTK) inhibitor developed by Sanofi for the treatment of autoimmune and inflammatory diseases. By selectively inhibiting BTK in B cells and innate immune cells (such as macrophages and mast cells), rilzabrutinib reduces autoantibody production and inflammatory signaling while aiming to preserve normal immune function due to its reversible, non-covalent binding profile. It is being evaluated across multiple indications, including immune thrombocytopenia (ITP), pemphigus vulgaris, and other immune-mediated disorders, where clinical studies have demonstrated clinically meaningful platelet responses and disease control with a generally favorable safety profile. Its oral administration and differentiated mechanism position it as a potential alternative to corticosteroids and biologics, though it remains under clinical development and has not yet received broad regulatory approval. The report provides Rilzabrutinib’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the Rilzabrutinib Market Report

The report provides insights into:

• A comprehensive product overview including the Rilzabrutinib MoA, description, dosage and administration, research and development activities in approved indications like Idiopathic thrombocytopenic purpura; as well as potential indication like Autoimmune haemolytic anaemia, Immunoglobulin G4-related disease, Asthma, Chronic urticaria, and Sickle cell anaemia.
• Elaborated details on Rilzabrutinib regulatory milestones and other development activities have been provided in Rilzabrutinib market report.
• The report also highlights Rilzabrutinib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Rilzabrutinib market report also covers the patents information, generic entry and impact on cost cut.
• The Rilzabrutinib market report contains current and forecasted Rilzabrutinib sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Rilzabrutinib market report also features the SWOT analysis with analyst views for Rilzabrutinib in approved and potential indications.

Methodology

The Rilzabrutinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Rilzabrutinib Analytical Perspective

• In-depth Rilzabrutinib Market Assessment

This Rilzabrutinib sales market forecast report provides a detailed market assessment of Rilzabrutinib for approved indication like Idiopathic thrombocytopenic purpura; as well as potential indication like Autoimmune haemolytic anaemia, Immunoglobulin G4-related disease, Asthma, Chronic urticaria, and Sickle cell anaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Rilzabrutinib sales data uptil 2034.

• Rilzabrutinib Clinical Assessment

The Rilzabrutinib market report provides the clinical trials information of Rilzabrutinib for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Rilzabrutinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Rilzabrutinib Market Potential & Revenue Forecast

• Projected market size for the Rilzabrutinib and its key indications
• Estimated Rilzabrutinib sales potential (Rilzabrutinib peak sales forecasts)
• Rilzabrutinib Pricing strategies and reimbursement landscape

Rilzabrutinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Rilzabrutinib Market positioning compared to existing treatments
• Rilzabrutinib Strengths & weaknesses relative to competitors

Rilzabrutinib Regulatory & Commercial Milestones

• Rilzabrutinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Rilzabrutinib Clinical Differentiation

• Rilzabrutinib Efficacy & safety advantages over existing drugs
• Rilzabrutinib Unique selling points  

Rilzabrutinib Market Report Highlights

• In the coming years, the Rilzabrutinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Rilzabrutinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Rilzabrutinib’s dominance.
• Other emerging products for Idiopathic thrombocytopenic purpura; as well as potential indication like Autoimmune haemolytic anaemia, Immunoglobulin G4-related disease, Asthma, Chronic urticaria, and Sickle cell anaemia are expected to give tough market competition to Rilzabrutinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Rilzabrutinib in approved and potential indications.
• Analyse Rilzabrutinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Rilzabrutinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Rilzabrutinib in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Rilzabrutinib? How strong is Rilzabrutinib’s clinical and commercial performance?
• What is Rilzabrutinib’s clinical trial status in each individual indications such as Idiopathic thrombocytopenic purpura; as well as potential indication like Autoimmune haemolytic anaemia, Immunoglobulin G4-related disease, Asthma, Chronic urticaria, and Sickle cell anaemia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Rilzabrutinib Manufacturers?
• What are the key designations that have been granted to Rilzabrutinib for approved and potential indications? How are they going to impact Rilzabrutinib’s penetration in various geographies?
• What is the current and forecasted Rilzabrutinib market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Rilzabrutinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Rilzabrutinib for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Rilzabrutinib? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.